Outlook Therapeutics shares fall 1.61% intraday after requesting a meeting with the US FDA.

Outlook Therapeutics, Inc. declined 1.61% in intraday trading. The company announced that it will present at the EURETINA Innovation Spotlight on September 3, 2025, in Paris, with the presentation titled "Optimising the treatment of retinal disease." Additionally, Outlook Therapeutics requested a meeting with the US FDA to discuss its investigational ophthalmic formulation of bevacizumab for retinal indications.